DMAC — DiaMedica Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401040 ·
Last close
$8.38
Market Cap
$452.16M
52W High
$11.00
52W Low
$5.24
ADV30
221,332
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -11,621,000 | -11,310,000 | 36,153,000 | 6,800,000 | 7,494,000 |
| Jun 2026 | 0 | — | -10,498,000 | -10,139,000 | 45,001,000 | 5,129,000 | 6,663,000 |
| Mar 2026 | 0 | — | -10,482,000 | -10,042,000 | 53,080,000 | 4,868,000 | 5,845,000 |
| Dec 2025 | 0 | — | -9,213,000 | -8,740,000 | 61,371,000 | 15,647,000 | 5,260,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-31,511,000
Investing CF
$-11,642,000
Financing CF
$44,173,000
CapEx
$-33,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-192,949,000
Inventory
—
Receivables
$244,000
ST Investments
$38,375,000
EBIT TTM
$-39,226,000
Pretax Income TTM
$-37,511,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,397,000 | -32,766,000 | 61,371,000 | 5,260,000 | 56,111,000 | -29,062,000 |
| Dec 2024 | 0 | -26,681,000 | -24,444,000 | 46,345,000 | 5,627,000 | 40,718,000 | -22,076,000 |
| Dec 2023 | 0 | -21,267,000 | -19,381,000 | 54,160,000 | 3,103,000 | 51,057,000 | -18,728,000 |
| Dec 2022 | 0 | -14,001,000 | -13,676,000 | 34,395,000 | 2,568,000 | 31,827,000 | -11,511,000 |
TTM Snapshot
Revenues TTM
$-45,000
NetIncome TTM
$-37,541,000
OpCashFlow TTM
—
Assets (Latest)
$45,001,000
Forward EPS
$-0.75
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $8.59 · call volume: 112 · put volume: 55
Expected Move to 2027-01-15:
±$3.63
(42.32%) —
implied range
$4.96 –
$12.23
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | $447.10M | $5.50 | — |
| ARVN | ARVINAS, INC. | $446.61M | $6.82 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $460.74M | $22.50 | — |
| EOLS | Evolus, Inc. | $442.80M | $6.69 | — |
| INDP | Indaptus Therapeutics, Inc. | $442.36M | $3.32 | — |
News headlines (Yahoo Finance, 1h cache)
DiaMedica (DMAC) Q3 2026 Earnings Call Transcript
2026-11-13 20:45 · Yahoo
DiaMedica Therapeutics Q3 Earnings Call Highlights
2026-11-13 15:14 · Yahoo
DiaMedica Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
2026-11-12 21:30 · Yahoo
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
2026-11-05 13:45 · Yahoo
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
2026-10-22 12:00 · Yahoo
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
2026-10-19 12:00 · Yahoo
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
2026-09-30 12:30 · Yahoo
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-02 12:30 · Yahoo
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
2026-08-26 13:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.